Research Papers Published

• "MFS transporters of Candida species and their role in clinical drug resistance" FEMS Yeast Res., 16(6): DOI No. 10.1093/femsyr/fow043 Impact Factor=
• "Newly identified motifs in Candida albicans Cdr1 protein nucleotide binding domains are pleiotropic drug resistance subfamily-specific and functionally asymmetric." Sci Rep., 6(30221): DOI No. 10.1038/srep30221 Impact Factor=
• "Resistance to antifungal therapies" Essays in Biochemistry, 61(1): 157 -166 Impact Factor= 3
• "Novel role of a family of major facilitator transporters in biofilm development and virulence of Candida albicans." Biochemical Journal, 460(2): 223 -235 Impact Factor= 4
• "ABC transporter Cdr1p harbors charged residues in the intracellular loop and nucleotide-binding domain critical for protein trafficking and drug resistance." FEMS Yeast Research, 15(5): DOI No. 10.1093/femsyr/fov036 Impact Factor= 3.3
• "In vitro effect of malachite green on Candida albicans involves multiple pathways and transcriptional regulators UPC2 and STP2." Antimicrob Agents Chemother, 56(1): 495 -506 Impact Factor= 4
• "Alanine scanning of all cysteines and construction of a functional cysteine-less Cdr1p, a multidrug ABC transporter of Candida albicans" BBRC, 417(1): 508 -513 Impact Factor= 2.5
• "W1038 near D-loop of NBD2 is a focal point for inter-domain communication in multidrug transporter Cdr1 of Candida albicans." BBA-BIOMEMBRANES, 1860(5): 865 -872 {ISSN: 0005-2736,} Impact Factor= 3.5
• "Quorum sensing: A less known mode of communication among fungi." Microbiological Research, 210(0): 51 -58 {ISSN: 0944-5013} Impact Factor= 3
• "Molecular Basis of Substrate Polyspecificity of the Candida albicans Mdr1p Multidrug/H+ Antiporter." Journal Of Molecular Biology, 430(5): 682 -692 {ISSN: 0022-2836} Impact Factor= 4.3
• "Identification of Genomewide Alternative Splicing Events in Sequential, Isogenic Clinical Isolates of Candida albicans Reveals a Novel Mechanism of Drug Resistance and Tolerance to Cellular Stresses" mSphere, 5(4): DOI No. 10.1128/mSphere.00608-20 {ISSN: 2379-5042} Impact Factor= 4.28
• "Glucose-The X Factor for the survival of human fungal pathogens and disease progression in the host" Microbiological Research, 247(126725): DOI No. 10.1016/j.micres.2021.126725 {ISSN: 0944-5013} Impact Factor= 3.9
• "Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes" Curr Drug Targets, 22(11): 1 -13 Impact Factor= 2.6
• "Metabolic flexibility and extensive adaptability governing multiple drug resistance and enhanced virulence in Candida albicans" Critical Reviews in Microbiology, 1(1): 1 -20 Impact Factor= 7.92
• "Glucose - The X factor for the survival of human fungal pathogens and disease progression in the host." Microbiological Research, 247(00): DOI No. 10.1016/j.micres.2021.126725 Impact Factor= 5.4
• "Natural products and their semi-synthetic derivatives against antimicrobial-resistant human pathogenic bacteria and fungi" Saudi Journal of Biological Sciences, 29(103376): DOI No. doi.org/10.1016/j.sjbs.2022.10 Impact Factor= 4.05
• "Quinidine drug resistance transporter knockout Candida cells modulate glucose transporter expression and accumulate metabolites leading to enhanced azole drug resistance" Fungal Genetics and Biology, 161(103713): DOI No. doi.org/10.1016/j.fgb.2022.103 Impact Factor= 3.88
• "ß-Nitrostyrene derivatives as broad range potential antifungal agents targeting fungal cell wall" European Journal of Medicinal Chemistry, 240(114609): DOI No. doi.org/10.1016/j.ejmech.2022 Impact Factor= 7.08
• "Glucose metabolic reprogramming and modulation in glycerol biosynthesis regulates drug resistance in clinical isolates of Candida" Journal of Appied Microbiology, 134(lxad091): DOI No. 10.1093/jambio/lxad091 {ISSN: 1364-5072} Impact Factor= 4.05
• "Physicochemical and Anti-fungal Studies of the Pharmaceutical Co-crystal/Salt of Fluconazole" ACS Molecular Pharmaceutics, https://d(https://d): DOI No. 10.1021/acs.molpharmaceut.3c00 {ISSN: 1543-8384} Impact Factor= 5.36
• "Dual Antifungal and Antiproliferative Activities of a Novel Protein Fraction from a Medicinally Important Herb Trillium govanianum Wall. ex. D. Don." Applied Biochemistry and Biotechnology, https://d(https://d): DOI No. doi.org/10.1007/s12010 {ISSN: 0273-2289} Impact Factor= 3.09
• "Pharmaceutical salts of azole anti-fungal drugs: physicochemical behaviour and activity studies" RSC Pharmaceutics, 1(4): 701 -715 Impact Factor=
• "The clinical praxis of bacteriocins as natural anti-microbial therapeutics" Archives of Microbiology, 206(11): DOI No. 10.1007/s00203-024-04152-8 Impact Factor= 2.3

Books Published

• "Antifungals: Mechanism of Action and Drug Resistance". Springer International Publishing Switzerland. {ISBN: 978-3-319-25302-2} pp 22
• "Candida Efflux ATPases and Antiporters in Clinical Drug Resistance". Springer International Publishing Switzerland. {ISBN: 978-3-319-25302-2} pp 24
• "Tools and Techniques to Study Multidrug Transporters of Yeasts". Springer International Publishing AG 2017. {ISBN: 978-3-319-49195-0} pp 24
• "Mechanisms of Drug Resistance in Fungi and Their Significance in Biofilms". Springer-Verlag Berlin Heidelberg. {ISBN: 978-3-642-53832-2} pp 22
• "Role of immunogenetics polymorphisms in infectious diseases". Academic Press. {ISBN: 978-0-323-90053-9} pp 22
• "Combating human fungal infections: Need for new antifungal drugs and therapies". Elsevier Science Publishers USA. {ISBN: 9780323961271} pp 25
• "Antifungal therapies and drug resistance". CRC Press. {ISBN: 9781032642864} pp 16